We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2006 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00406172
First Posted: December 4, 2006
Last Update Posted: December 5, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Asociación para Evitar la Ceguera en México
  Purpose
To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.

Condition Intervention Phase
Cystoid Macular Edema Drug: Bevacizumab Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Pseudophakic eyes with macular edema

Exclusion Criteria:

  • Other retinopathies
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00406172


Contacts
Contact: Victoria Cubas-Lorenzo, MD (55) 10841400 ext 1171 retinamex@yahoo.com

Locations
Mexico
APEC Recruiting
México D.F., Mexico, 03040
Contact: Victoria Cubas-Lorenzo, MD    (55) 10841400 ext 1171    retinamex@yahoo.com   
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Victoria Cubas-Lorenzo, MD APEC México
  More Information

ClinicalTrials.gov Identifier: NCT00406172     History of Changes
Other Study ID Numbers: APEC 0016
First Submitted: November 30, 2006
First Posted: December 4, 2006
Last Update Posted: December 5, 2006
Last Verified: November 2006

Additional relevant MeSH terms:
Edema
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents